Lausanne, January 17th 2024 – Rheon Medical is excited to share the results from a two-year study conducted in Lausanne, Switzerland, showcasing the safety and efficacy of the eyeWatch system. This monocentric study, involving 42 patients with refractory glaucoma following multiple unsuccessful surgeries, marks a significant advancement in ophthalmic research.
This study, the first to present comprehensive 2-year results on the eyeWatch system, revealed very positive outcomes for patients treated with the eyeWatch implant in combination with the eyePlate. The mean baseline Intraocular Pressure (IOP) decreased from 23.2±7.2 mmHg before surgery to 11.9 ± 4.4 mmHg at 12 months and further to 11.5 ± 3.0 mmHg at the 24-month mark.
Equally compelling is the observed reduction in glaucoma medication dependence. The mean number of medications decreased significantly from 2.9±0.9 before surgery to 0.7±0.9 at 12 months and maintained a low level at 1.0±0.9 at 24 months.
The success rates of the eyeWatch system are truly noteworthy, with a qualified success rate of 93% at 12 months and 84% at the 24-month follow-up. Complete success rates stand at 46% and 40% at 12 and 24 months, respectively.
Notably, all surgeries were performed without the use of Mitomycin C (MMC), underlining the eyeWatch system’s efficacy and safety without relying on adjunctive agents.
Complications were reported in only 7 out of the 42 patients (16%), while none of the patients required any surgical re-intervention. This favorable outcome can be attributed to the unique adjustability feature of the eyeWatch implant, allowing for precise pressure control, thereby avoiding hypotony and reducing related complications.
CEO Nikos Stergiopulos expressed excitement about the results:
“We are delighted to announce the publication of the first paper showcasing 2-year data on the eyeWatch system, affirming its long-term efficacy and safety. These results firmly position the eyeWatch as the most efficient clinical solution today for treating refractory glaucoma. As we currently expand into multiple markets, we hope that more individuals will benefit from our groundbreaking devices.”
For more in-depth information on the study and its implications, access the full paper https://pubmed.ncbi.nlm.nih.gov/37974333/.
Contact information:
e-mail: [email protected]